12:00 AM
Dec 21, 2009
 |  BC Week In Review  |  Company News  |  Deals

Adimab, Merck, Pfizer, Roche deal

Adimab announced deals with Pfizer and an undisclosed company to use its yeast-based antibody discovery technology to identify fully human antibodies. Adimab will identify mAbs against undisclosed CNS/pain targets for Pfizer, which will have rights to commercialize the resulting mAbs. Adimab will identify mAbs against...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >